/OMI
OMI Stock - Owens & Minor, Inc.
Healthcare|Medical - DistributionNYSE
$2.84-9.84%
$0.31 (-9.84%) • Dec 19
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.65
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+40.8%upside
Target: $4.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OMI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.81 – $2.87
TARGET (TP)$4.00
STOP LOSS$2.61
RISK/REWARD1:5.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.36
52W High$15.54
52W Low$2.38
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.70B | $10.33B | $9.96B | $9.79B | $8.48B |
| Gross Profit | $2.22B | $2.13B | $1.83B | $1.51B | $1.28B |
| Gross Margin | 20.7% | 20.6% | 18.3% | 15.5% | 15.1% |
| Operating Income | $-207,769,000 | $104.51M | $142.91M | $368.47M | $204.12M |
| Net Income | $-362,686,000 | $-41,301,000 | $22.39M | $221.59M | $29.87M |
| Net Margin | -3.4% | -0.4% | 0.2% | 2.3% | 0.4% |
| EPS | $-4.73 | $-0.55 | $0.30 | $3.05 | $0.47 |
Company Overview
Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; and various programs to provide logistics and marketing solutions to its suppliers. The Global Products segment manufactures and sources medical surgical products for the prevention of healthcare-associated infections across the acute and alternate site channels. This segments products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. It provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. The company was founded in 1882 and is headquartered in Richmond, Virginia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
29%
Hold / Neutral
4
57%
Sell / Underperform
1
14%
Analyst Consensus🔴 Bearish
2 Bullish5 Neutral/Bearish
Price Targets
$23
Average Target
↑ 692.3% Upside
Now
$4
Low
$23
Average
$55
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 3rd 2025 | UBS | Downgrade | Neutral | $4 |
| July 19th 2024 | Citigroup | Upgrade | Buy | $19← $24 |
| February 26th 2024 | Leerink Partners | Initiation | Market Perform | $24 |
| January 3rd 2024 | Barclays | Initiation | Equal Weight | $21 |
| October 13th 2022 | Citigroup | Downgrade | Neutral | $18← $52 |
| October 12th 2022 | BofA Securities | Downgrade | Underperform | $17← $43 |
| October 12th 2022 | Robert W. Baird | Downgrade | Neutral | $22← $62 |
| April 26th 2022 | Citigroup | Resumed | Buy | $55 |
Earnings History & Surprises
OMIBeat Rate
83%
Last 18 quarters
Avg Surprise
+17.0%
EPS vs Estimate
Beats / Misses
15/2
1 met exactly
Latest EPS
$0.25
Q4 2025
EPS Surprise History
Q1 24
+1.5%
$0.69vs$0.68
Q2 24
+11.8%
$0.19vs$0.17
Q3 24
+9.1%
$0.36vs$0.33
Q4 24
+5.0%
$0.42vs$0.40
Q1 25
+3.8%
$0.55vs$0.53
Q2 25
+15.0%
$0.23vs$0.20
Q3 25
-3.7%
$0.26vs$0.27
Q4 25
+8.7%
$0.25vs$0.23
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 27, 2026 | $0.22 | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.23 | $0.25 | +8.7% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $0.27 | $0.26 | -3.7% | ✗ MISS |
Q2 2025 | May 8, 2025 | $0.20 | $0.23 | +15.0% | ✓ BEAT |
Q1 2025 | Feb 28, 2025 | $0.53 | $0.55 | +3.8% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $0.40 | $0.42 | +5.0% | ✓ BEAT |
Q3 2024 | Aug 2, 2024 | $0.33 | $0.36 | +9.1% | ✓ BEAT |
Q2 2024 | May 3, 2024 | $0.17 | $0.19 | +11.8% | ✓ BEAT |
Q1 2024 | Feb 20, 2024 | $0.68 | $0.69 | +1.5% | ✓ BEAT |
Q4 2023 | Nov 3, 2023 | $0.36 | $0.44 | +22.2% | ✓ BEAT |
Q3 2023 | Aug 4, 2023 | $0.16 | $0.18 | +12.5% | ✓ BEAT |
Q2 2023 | May 5, 2023 | $-0.09 | $0.05 | +155.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $0.39 | $0.28 | -28.2% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $0.39 | $0.41 | +5.1% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $0.76 | $0.76 | 0.0% | = MET |
Q2 2022 | May 3, 2022 | $0.77 | $0.96 | +24.7% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $0.67 | $0.81 | +20.9% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.55 | $0.74 | +34.5% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $0.99 | $1.06 | +7.1% | ✓ BEAT |
Latest News
Owens & Minor Changes Name To Accendra Health; To Trade Under "ACH" On NYSE
➖ NeutralBenzinga•Dec 18, 2025, 09:09 PM
Owens & Minor shares are trading lower after UBS downgraded the stock from Buy to Neutral and cut its price target from $7 to $4.
📉 NegativeBenzinga•Nov 3, 2025, 05:53 PM
UBS Downgrades Owens & Minor to Neutral, Lowers Price Target to $4
📉 NegativeBenzinga•Nov 3, 2025, 11:20 AM
OMI stock has given up its prior gain. Owens & Minor shares were trading higher after the company reported better-than-expected Q3 adjusted EPS results and a year-over-year increase in Q3 sales results.
➖ NeutralBenzinga•Oct 31, 2025, 01:57 PM
Owens & Minor shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results and a year-over-year increase in Q3 sales results.
📈 PositiveBenzinga•Oct 31, 2025, 01:26 PM
Owens & Minor Affirms FY2025 Adj EPS Guidance of $1.02-$1.07 vs $1.03 Est; Affirms FY2025 Sales Guidance of $2.760B-$2.820B vs $2.777B Est
➖ NeutralBenzinga•Oct 30, 2025, 08:11 PM
Owens & Minor Q3 2025 Adj. EPS $0.25 Beats $0.23 Estimate, Sales $697.264M Up From $686.846M YoY
📈 PositiveBenzinga•Oct 30, 2025, 08:11 PM
Owens & Minor shares are trading higher after the company announced it has entered into a definitive agreement for the sale of the Company's Products & Healthcare Services segment to Platinum Equity.
📈 PositiveBenzinga•Oct 7, 2025, 08:20 PM
Owens & Minor To Sell Products & Healthcare Services Segment To Platinum Equity For $375M, Retains 5% Stake And Over $150M In Tax Assets
📈 PositiveBenzinga•Oct 7, 2025, 08:18 PM
Noble Corporation, Q2 Holdings, Waystar Holding And Hecla Mining Will Replace Owens & Minor, B&G Food, Jack In The Box And Simulations Plus In The S&P SmallCap 600, Respectively
➖ NeutralBenzinga•Sep 5, 2025, 09:49 PM•Also: , ,
JP Morgan Maintains Underweight on Owens & Minor, Lowers Price Target to $6
📉 NegativeBenzinga•Aug 27, 2025, 03:02 PM•Also:
Owens & Minor tanks as FY profit outlook falls short of estimates
📉 NegativeSeeking Alpha•Aug 11, 2025, 02:19 PM
Owens & Minor cancels Rotech buyout over regulatory issues
📉 NegativeSeeking Alpha•Jun 5, 2025, 02:13 PM
Frequently Asked Questions about OMI
What is OMI's current stock price?
Owens & Minor, Inc. (OMI) is currently trading at $2.84 per share. The stock has moved -9.84% today.
What is the analyst price target for OMI?
The average analyst price target for OMI is $4.00, based on 1 analyst.
What sector is Owens & Minor, Inc. in?
Owens & Minor, Inc. operates in the Healthcare sector, specifically within the Medical - Distribution industry. The company is traded on the NYSE exchange.
What is OMI's market cap?
Owens & Minor, Inc. has a market capitalization of $0.22 billion, making it a small-cap company.
Does OMI pay dividends?
No, Owens & Minor, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRS
Aclaris Therapeutics, Inc.
$3.14
Mkt Cap: $0.3B
ALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
BIOA
BioAge Labs, Inc.
$13.39
Mkt Cap: $0.5B
CABA
Cabaletta Bio, Inc.
$2.39
Mkt Cap: $0.2B
CGC
Canopy Growth Corporation
$1.48
Mkt Cap: $0.4B
CVRX
CVRx, Inc.
$8.03
Mkt Cap: $0.2B
EDIT
Editas Medicine, Inc.
$2.34
Mkt Cap: $0.2B
HITI
High Tide Inc.
$2.77
Mkt Cap: $0.2B
OM
Outset Medical, Inc.
$3.70
Mkt Cap: $0.1B
SGHT
Sight Sciences, Inc.
$8.45
Mkt Cap: $0.4B
Explore stocks similar to OMI for comparison